» Articles » PMID: 37344601

Multiphysics Simulation of Local Transport and Absorption Coupled with Pharmacokinetic Modeling of Systemic Exposure of Subcutaneously Injected Drug Solution

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2023 Jun 21
PMID 37344601
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Subcutaneous (SC) injectables have become more acceptable and feasible for administration of biologics and small molecules. However, efficient development of these products is limited to costly and time-consuming techniques, partially because absorption mechanisms and kinetics at the local site of injection remain poorly understood.

Objective: To bridge formulation critical quality attributes (CQA) of injectables with local physiological conditions to predict systemic exposure of these products.

Methodology: We have previously developed a multiscale, multiphysics computational model to simulate lymphatic absorption and whole-body pharmacokinetics of monoclonal antibodies. The same simulation framework was applied in this study to compute the capillary absorption of solubilized small molecule drugs that are injected subcutaneously. Sensitivity analyses were conducted to probe the impact by key simulation parameters on the local and systemic exposures.

Results: This framework was capable of determining which parameters had the biggest impact on small molecule absorption in the SC. Particularly, membrane permeability of a drug was found to have the biggest impact on drug absorption kinetics, followed by capillary density and drug diffusivity.

Conclusion: Our modelling framework proved feasible in predicting local transport and systemic absorption from the injection site of small molecules. Understanding the effect of these properties and how to model them may help to greatly expedite the development process.

Citing Articles

Leveraging Model Master Files for Long-Acting Injectables.

Gong Y, Hopefl R, Li T, Hooker A, Silva D, Alam K Pharm Res. 2025; .

PMID: 39875758 DOI: 10.1007/s11095-025-03824-4.

References
1.
Turner M, Balu-Iyer S . Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins. J Pharm Sci. 2018; 107(5):1247-1260. PMC: 5915922. DOI: 10.1016/j.xphs.2018.01.007. View

2.
Brohem C, Cardeal L, Tiago M, Soengas M, de Moraes Barros S, Maria-Engler S . Artificial skin in perspective: concepts and applications. Pigment Cell Melanoma Res. 2010; 24(1):35-50. PMC: 3021617. DOI: 10.1111/j.1755-148X.2010.00786.x. View

3.
Viola M, Sequeira J, Seica R, Veiga F, Serra J, Santos A . Subcutaneous delivery of monoclonal antibodies: How do we get there?. J Control Release. 2018; 286:301-314. DOI: 10.1016/j.jconrel.2018.08.001. View

4.
Mehta C, Narayan R, Nayak U . Computational modeling for formulation design. Drug Discov Today. 2018; 24(3):781-788. DOI: 10.1016/j.drudis.2018.11.018. View

5.
Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner D, Dressman J . Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. Eur J Pharm Sci. 2019; 143:105170. DOI: 10.1016/j.ejps.2019.105170. View